Allergan had a 6.3 percent drop in sales in the first quarter ended March 31 to $994.6 million. This translated to a 0.4 percent drop in constant currencies. Eye-care pharmaceuticals fell by 3.8 percent (or grew by 2.3 percent at constant currencies) to $473.6 million. Earnings for the three months plummeted by 59 percent to $44.7 million, which the company said was because of charges from a 5 percent cut in its workforce, announced in February.